Specificity, Safety, Efficacy of EGFRvIII-Retargeted Oncolytic HSV for Xenotransplanted Human Glioblastoma

Irene Appolloni(University of Genoa), Paolo Malatesta(Ospedale Policlinico San Martino), Francesco Alessandrini(University of Genoa), Gabriella Campadelli‐Fiume(University of Bologna), Laura Menotti(University of Bologna), Noemi Piga(University of Genoa), Davide Ceresa(University of Genoa), Francesca Piaggio(Ospedale Policlinico San Martino), Elisa Avitabile(University of Bologna), Daniela Marubbi(Ospedale Policlinico San Martino)

Viruses

August 24, 2021

10.3390/v13091677

Cited by 11

Related Papers

Entry of herpes simplex virus 1 in BJ cells that constitutively express viral glycoprotein D is by endocytosis and results in degradation of the virus

|Journal of Virology|1988|201

Dissecting the effects of preconditioning with inflammatory cytokines and hypoxia on the angiogenic potential of mesenchymal stromal cell (MSC)-derived soluble proteins and extracellular vesicles (EVs)

|Biomaterials|2020|136

Eradication of glioblastoma by immuno-virotherapy with a retargeted oncolytic HSV in a preclinical model

|Oncogene|2019|78

Herpes simplex virus glycoprotein D is sufficient to induce spontaneous pH-independent fusion in a cell line that constitutively expresses the glycoprotein

|Virology|1988|53

Construction and properties of a cell line constitutively expressing the herpes simplex virus glycoprotein B dependent on functional alpha 4 protein synthesis

|Journal of Virology|1986|38